NUVB · Nuvation Bio Inc.

Track NUVB — free

$7.02 +0.19 (+2.71%)

Market Cap

$2.55B

351.12M

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 11 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 6, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Strong Sentiment Very Bullish Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +17%

above

Price vs 50-day avg +13%

above

RSI (14) 57

neutral

MACD trend Positive

52-week position 60%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return +5%

trailing

6-month return +16%

trailing

YTD return −24%

this year

Relative strength +4%

vs S&P · 6-mo

Sentiment

smart money

Very Bullish

Trend (MA cross) No cross

50d $6 › 200d $6 — 50d above 200d

Institutional flow Accumulating

+3% holders QoQ · +38 funds added

Insider flow Accumulating

Net +$118.3K over 90 days · 0% sells

Short interest Falling

15.22% of float · ▼ -4.0% MoM · 8.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

241 holders — near 3-yr high, broad support

Squeeze score 70

high risk · 0–100

Fundamentals

Excellent

Revenue growth +699%

Y/Y

Gross margin 1%

expanding

EPS growth +72%

Y/Y

Balance sheet $111.2M

net cash

Quant / Vol

risk profile

Very High

Volatility 88%

annualized · 1-yr

Max drawdown −58%

past year

ATR 6.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

0 · 4 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+17% Bullish

Price vs 50-day avg

+13% Bullish

RSI (14)

57 Neutral

MACD trend

Positive Bullish

52-week position

60% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 4 of 6

Trend (MA cross) No cross

50d $6 › 200d $6 — 50d above 200d

Institutional flow Accumulating

+3% holders QoQ · +38 funds added

Insider flow Accumulating

Net +$118.3K over 90 days · 0% sells

Short interest Falling

15.22% of float · ▼ -4.0% MoM · 8.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

241 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $3 Now $7 · 60% Range high $10

vs 200-day avg +17% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
approximately 160 new patient starts	160	Q2 2026	—
cash, cash equivalents, and marketable securities	$533.7M	Q1 2026	—
new patients started treatment on IBTROZI	216	Q4 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NUVB Nuvation Bio Inc. this stock	$2.55B	-23.8%	+699.0%	—	15.2%
ONC BeOne Medicines Ltd.	$557.05B	+21.5%	+22179.2%	856.5	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$136.93B	+19.2%	+46.2%	31.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$86.39B	+7.1%	+20.8%	20.8	3.3%
MRNA Moderna, Inc.	$69.62B	+352.1%	+4.3%	—	12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

241

% held: 68.2%
Net QoQ: +17.1M sh
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

185

View

Short & Settlement

Short Interest Falling

Shares short

53.4M

Days to cover: 8.7d
Change: -2.2M sh

View

Short Volume

Short vol %

50%

As of: Aug 20, 2026

Short Total

View

Fails to Deliver

FTD shares

24.0K

Value: $159.8K
As of: Jul 28, 2026

View

Off-Exchange

Off-exchange %

50.2%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$118.3K

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$62.9M

Net income (FY): $-204.6M
EPS diluted: $-0.60

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 13

View

Proposed Sales

Value

$696.0K

Shares: 100.0K
Filed: Aug 19, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
NUVB	+12.0%	+5.2%	+15.6%	+7.9%	-23.8%
SPY	-2.0%	+3.3%	+11.2%	+2.1%	+11.8%
vs SPY	+13.9%	+1.9%	+4.4%	+5.8%	-35.6%

Key facts CIK 1811063 CUSIP 67080N101 13F (30d) 228 filings 224 filers Visit website Investor relations

NUVB · Nuvation Bio Inc.

Price & Indicators

Up next

AI Brief

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance